Theravance Biopharma, Inc. - Ordinary Shares (TBPH) News

Theravance Biopharma, Inc. - Ordinary Shares (TBPH): $8.40

-0.22 (-2.55%)

POWR Rating

Component Grades













Add TBPH to Watchlist
Sign Up

Industry: Biotech


of 392

in industry

Filter TBPH News Items

TBPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TBPH News Highlights

  • TBPH's 30 day story count now stands at 18.
  • Over the past 21 days, the trend for TBPH's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • BEAT, BIO and GSK are the most mentioned tickers in articles about TBPH.

Latest TBPH News From Around the Web

Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q4 2021 Results - Earnings Call Transcript

Theravance Biopharma, Inc. (TBPH) Q4 2021 Earnings Conference Call February 23, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Commercial and Medical Affairs Rick Graham – Senior Vice President, Research and Development Andrew Hindman...

SA Transcripts on Seeking Alpha | February 24, 2022

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021.

Yahoo | February 23, 2022

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Yahoo | February 22, 2022

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, at 2:10 pm ET (11:10 am PT/7:10 pm GMT).

Yahoo | February 22, 2022

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Yahoo | February 18, 2022

Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | February 18, 2022

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

Yahoo | February 16, 2022

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Yahoo | February 16, 2022

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

Yahoo | February 15, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5507 seconds.